+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and performance of the Glean Urodynamics System for monitoring the lower urinary tract in adults aged 22 and older. This open-label, single-arm trial focuses on patients who are candidates for urodynamic studies, aiming to assess how well the device works both inside the clinic and during extended home monitoring. Participants will have the Glean Urodynamics System inserted for an ambulatory monitoring period in the clinic. After this, they will continue monitoring at home with the Glean Bladder Sensor in place for up to 24 hours. The sensor is removed within 24 hours after insertion. Seven days following sensor removal, participants will provide a urine sample and receive a follow-up phone call 14 days after removal to check on any adverse events. Throughout the study, participants will be monitored for any qualifying adverse events related to the Glean Urodynamics System from enrollment until 14 days after device removal. The study includes urine sample collection and regular follow-up to ensure safety and device performance. Total participation includes the in-clinic monitoring, home monitoring, sample collection, and follow-up calls extending up to about two weeks post device removal.

Age: 22Years +All GendersPhase Not Applicable
9 locations
E

Actively Recruiting

This research aims to evaluate the safety and effectiveness of the FemPulse System, a non-implanted electrical stimulation device, for treating Overactive Bladder OAB in women aged 21 years and older. The study compares this device with medication treatment to better understand options for managing OAB symptoms such as urinary urgency and frequency. Participants are randomly assigned to one of two groups one group receives the FemPulse non-implanted vaginal electrical stimulation device, while the other group receives medication for OAB. The study is designed as a parallel interventional trial without masking. Treatments and procedures will be followed and assessed over a period extending to the studys completion in late 2027. During the study, participants will undergo regular assessments including monitoring the mean change in the number of voids per day over six months. They will be expected to comply with study procedures such as consistent medication use, fluid intake, and diary completion. Researchers will monitor safety and effectiveness outcomes throughout the trial period, with the primary completion date in May 2027 and full study completion at the end of 2027.

Age: 21Years +FEMALEPhase Not Applicable
15 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of the Altaviva system, a programmable neurostimulation device used to treat Urge Urinary Incontinence UUI. This prospective, multicenter study focuses on understanding how well this device performs over time in patients diagnosed with UUI. The study is sponsored by MedtronicNeuro and aims to assess outcomes up to 60 months after treatment. Participants in this study will receive treatment with the Altaviva system, which delivers electrical stimulation to the tibial nerve to provide tibial neuromodulation therapy. The study involves a single group of participants and does not use masking or randomization. The treatment and follow-up will continue for an extended period, with the primary endpoint measured at 60 months to evaluate durability and sustained effectiveness. During the study, participants will be asked to complete study questionnaires, attend scheduled visits, and operate the Altaviva system as directed. Researchers will assess safety and treatment outcomes through a variety of measures, including a 3-day voiding diary, to track urinary urge incontinence episodes. Patients will be monitored closely to ensure adherence and study protocol compliance throughout the long-term follow-up period, which lasts until November 2032.

Age: 18Years +All GendersPhase Not Applicable
19 locations